Alliance Commends Bipartisan Introduction of Ensuring Pathways to Innovative Cures Act pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
With no cure in sight, any new approval ushers in hope, including with an agent like Leqembi that slowed progression of the disease an average of 27% in research.
The Daily Record welcomes letters to the editor and opinion columns on public policy issues that affect Maryland businesses and the legal community. Letters to the editor should be 300 words or less. Columns can be up to 800 words. All are subject to editing for length or clarity. Submissions must include the writer’s name, address and a daytime phone number for confirmation. They can be sent to Editor Thomas Baden Jr. at tbaden@thedailyrecord.com.
New Analysis Shows International Reference Drug Pricing Would Have a Catastrophic Impact on Alzheimer s Disease Research
Proposed Policy Would Likely Eliminate Future Clinical Development Programs in Alzheimer s Research, Impacting Millions of Patients and Their Families
News provided by
Share this article
Vital Transformation
WASHINGTON, April 22, 2021 /PRNewswire/
The number of Americans aged 65 and older with Alzheimer s disease (AD) is expected to more than double from 6.2 million today to 12.7 million by 2050. Currently, there are no treatments available to stop or slow the progression of the disease. At the same time, large pharmaceutical companies have already downsized investment into AD and other neurological disorders by more than 50 percent due to the associated high risk of study failure for these diseases. International reference pricing proposals (including International Pricing Index or Most Favored Nation ), currently under consideration by the U.S. Congr